Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01394055 · ClinicalTrials.gov registry record · Phase 1

Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic Gastroparesis

A Phase 1 study of Gastroparesis and Gastrointestinal Motility Disorder, sponsored by Motus Therapeutics.

Completed
Registry status
Phase 1
Development phase
20
Enrollment target
1
Study location

NCT01394055 is a Phase 1 study of Gastroparesis and Gastrointestinal Motility Disorder that has completed, run by Motus Therapeutics. The registered enrollment target is 20 participants, below the 302-participant average among 44 other Gastroparesis trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01394055, a Phase 1 study of Gastroparesis and Gastrointestinal Motility Disorder, has completed, sponsored by Motus Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) profile and the safety and tolerability of RM-131 in patients with diabetes mellitus and delayed gastric emptying.

Interventions

  • DRUG Placebo
  • DRUG RM-131

Study Locations (1)

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2011-07
Est. Completion 2012-12
Phase Phase 1

Sponsor

Motus Therapeutics

7 total trials

What the Registry Record Tells You About NCT01394055

The ClinicalTrials.gov registry entry for NCT01394055 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 302-participant average among 44 other Gastroparesis trials with a reported enrollment target (93% lower). The listed sponsor is Motus Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Gastroparesis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01394055 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT01394055 about?

NCT01394055 is a clinical study titled "Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic Gastroparesis". The purpose of this study is to evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) profile and the safety and tolerability of RM-131 in patients with diabetes mellitus and delayed gastric emptying.

What is the current status of trial NCT01394055?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2011-07. Estimated completion is 2012-12.

What conditions does trial NCT01394055 study?

This clinical trial studies the following conditions: Gastroparesis, Gastrointestinal Motility Disorder, Diabetes Mellitus Type 1 and 2, Diabetes Mellitus Complications.

What interventions are being tested in trial NCT01394055?

The interventions under investigation include: Placebo (DRUG), RM-131 (DRUG).

Who is sponsoring clinical trial NCT01394055?

This trial is sponsored by Motus Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01394055 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Gastroparesis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.